Prognostic Significance of the Systemic Inflammation Response Index (SIRI) in Patients with Hodgkin Lymphoma.

Interest in biomarkers reflecting the inflammatory nature of Hodgkin lymphoma (HL) is increasing. This study aimed to evaluate the prognostic significance of the Systemic Inflammation Response Index (SIRI) in patients with HL. In this study, 105 patients diagnosed with classical HL at the Hematology Clinic of Recep Tayyip Erdoğan University Faculty of Medicine between January 2015 and April 2025 were retrospectively evaluated. Patients were divided into 2 groups according to the SIRI cut-off value. A high SIRI (≥3.78) was significantly associated with advanced disease stage, poor performance status, higher IPS-7 and IPS-3 scores, non-response or partial response to treatment, relapse, and increased mortality. A positive correlation was found between SIRI and IPS 7 scores ( < 0.001, rho = 0.355). In the univariate analysis for progression-free survival (PFS), hemoglobin, IPS 7 score, and SIRI were identified as prognostic factors; in the multivariate analysis, high SIRI was identified as an independent prognostic factor ( = 0.033). In the univariate analysis for overall survival (OS), age, hemoglobin, albumin, lymphocyte count, IPS 7 score, and SIRI were identified as prognostic factors; and, in the multivariate analysis, age over 45 and high SIRI were identified as independent prognostic factors ( = 0.016, = 0.012). In the survival analysis, high SIRI levels were associated with shorter PFS and OS ( = 0.001, < 0.001). Additionally, PFS and OS durations were shorter in patients with high IPS 7 scores ( < 0.001, < 0.001). A high SIRI prior to treatment was identified as an independent prognostic factor in HL patients and was associated with shorter PFS and OS. This index may help identify high-risk patients and assist clinicians in their decision-making processes by enabling individualized risk assessment.